Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05909982
Other study ID # PROTECT-1b
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date April 1, 2023
Est. completion date March 31, 2024

Study information

Verified date June 2023
Source Capital Medical University
Contact Xunming Ji, MD
Phone +86-10-83198952
Email jixm@ccmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Ischemic post-conditioning is a neuroprotective strategy attenuating reperfusion injury in animal stroke models. The investigators have conducted a 3 + 3 dose-escalation trial to demonstrate the safety and tolerability of ischemic post-conditioning incrementally for a longer duration of up to 5 min × 4 cycles in stroke patients undergoing mechanical thrombectomy. This study aims to assess the infarct volume after ischemic post-conditioning in patients with acute ischemic stroke who are treated with mechanical thrombectomy.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date March 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years; - Acute ischemic stroke within 24 hours from stroke onset (or from time last known well) to groin puncture; - Previous mRS = 2; - Baseline NIHSS = 6; - Baseline ASPECTS = 6; - With an occlusion of unilateral middle cerebral artery M1 segment/distal intracranial carotid artery; - Successful recanalization (mTICI = 2b) after thrombectomy confirmed by DSA; - Written informed consent provided by the patients or their legal relatives. Exclusion Criteria: - Confirmed or clinically suspected cerebral vasculitis/fibromuscular dysplasia; - Difficulty in reaching the designated position of the balloon used for ischemic post-conditioning; - Stenting in the middle cerebral artery M1 segment/distal intracranial carotid artery during thrombectomy; - > 2 times balloon dilations as rescue therapy due to angioplasty during thrombectomy; - Moderate/severe residual stenosis (= 50%) in the offending artery after thrombectomy; - Patients with contraindications to MRI; - Other conditions that the investigator considered inappropriate for inclusion.

Study Design


Intervention

Procedure:
Mechanical thrombectomy combined with ischemic post-conditioning
Ischemic post-conditioning will be applied after successful recanalization of the culprit artery by thrombectomy. Ischemic post-conditioning consists of briefly repeated four cycles × 2 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.

Locations

Country Name City State
China Tianjin Huanhu Hospital Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Capital Medical University

Country where clinical trial is conducted

China, 

References & Publications (1)

Wu L, Zhang B, Zhao W, Ji X, Wei M. Ischemic post-conditioning in acute ischemic stroke thrombectomy: A phase-I duration escalation study. Front Neurosci. 2022 Dec 8;16:1054823. doi: 10.3389/fnins.2022.1054823. eCollection 2022. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Safety outcome (mortality at 90 days) 90-day mortality 90 days after procedure
Other Safety outcome (the proportion of symptomatic intracranial hemorrhage within 24 hours) The proportion of symptomatic intracranial hemorrhage within 24 hours after procedure Within 24 hours after procedure
Other Safety outcome (the proportion of intracranial hemorrhage within 24 hours) The proportion of intracranial hemorrhage within 24 hours after procedure Within 24 hours after procedure
Other Safety outcome (the proportion of malignant brain edema within 24 hours) The proportion of malignant brain edema within 24 hours after procedure Within 24 hours after procedure
Other Procedure-related complications Vascular perforation/rupture, vessel dissection, severe vasospasm, rupture of the balloon used for post-conditioning During the procedure
Primary Infarct volume Infarct volume at 72 hours after procedure 72 hours after procedure
Secondary The progression of infarct volume Difference of infarct volume between baseline and 72 hours after procedure Baseline and 72 hours after procedure
Secondary The proportion of functional independence at 90 days The modified Rankin Scale (mRS) score of 0-2 at 90 days after procedure; the mRS is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability, and 6=death) 90 days after procedure
Secondary The proportion of favorable outcome at 90 days The mRS score of 0-3 at 90 days after procedure; the mRS is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability, and 6=death) 90 days after procedure
Secondary The distribution of the mRS score at 90 days The distribution of the mRS score at 90 days after procedure; the mRS is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability, and 6=death) 90 days after procedure
Secondary National Institute of Health Stroke Scale (NIHSS) score NIHSS score at 24 hours after procedure; the NIHSS ranges from 0 to 42, with higher scores indicating more severe neurologic deficits 24 hours after procedure
Secondary The proportion of early neurological improvement NIHSS 0-2 or =8 lower than baseline NIHSS score at 24 hours after procedure; the NIHSS ranges from 0 to 42, with higher scores indicating more severe neurologic deficits 24 hours after procedure
Secondary NIHSS score at 7 days after procedure/discharge NIHSS score at 7 days after procedure/discharge; the NIHSS ranges from 0 to 42, with higher scores indicating more severe neurologic deficits 7 days after procedure/discharge
Secondary Recanalization rate Recanalization rate at 24 hours after procedure (mTICI =2b) 24 hours after procedure
Secondary Hemodynamic assessment Hemodynamic assessment within 24 hours after procedure Within 24 hours after procedure
See also
  Status Clinical Trial Phase
Recruiting NCT06113848 - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy Phase 3
Completed NCT04069546 - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency N/A
Active, not recruiting NCT05700097 - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Phase 2
Recruiting NCT06058130 - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis N/A
Recruiting NCT04415164 - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke Phase 4
Recruiting NCT05363397 - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke Phase 2
Completed NCT05429658 - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System N/A
Recruiting NCT05390580 - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct N/A
Enrolling by invitation NCT05515393 - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke Phase 2
Active, not recruiting NCT05070260 - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo Phase 2/Phase 3
Terminated NCT05547412 - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed NCT03366818 - New Stent Retriever, VERSI System for AIS N/A
Not yet recruiting NCT05293080 - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE Phase 3
Not yet recruiting NCT06040476 - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS) Phase 2
Completed NCT02223273 - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke) N/A
Completed NCT02586233 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke Phase 1/Phase 2
Not yet recruiting NCT01594190 - Physical Activity Immediately After Acute Cerebral Ischemia N/A
Terminated NCT01694381 - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor Early Phase 1
Completed NCT01120301 - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Phase 3
Completed NCT00963989 - Imaging Guided Patient Selection for Interventional Revascularization Therapy N/A